Compensating Participants in Clinical Research: Current Thinking
Sponsors, researchers and Institutional Review Boards (IRBs) are often wary about payments in research participation, citing concerns about coercion and undue influence, whether real or perceived, and have avoided payments that are “too high.” New research on how people make decisions about research participation, and new approaches to this question, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.
The WIRB-Copernicus Group® (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research. For more information, visit www.wcgclinical.com/.